Clinical trials: Methylation
Cancer
iDentification and vAlidation Model of Liquid biopsY Based cfDNA Methylation and pRotEin biomArKers for Pancreatic Cancer (DAYBREAK Study)
DAYBREAK is a prospective, multi-omics, observational study aimed at early detecting pancreatic cancer by combined assays for biomarkers of cfDNA methylation, serum protein markers, blood miRNA markers and others, in which of 450…
- Trial name
- NCT05495685
- Where
- China
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Changhai Hospital
Appendiceal Cancer, Appendiceal Adenocarcinoma
Molecular Profiling for Risk Stratification in Appendiceal Cancer
This study investigates integrated epigenetic and epitranscriptomic features of appendiceal cancer using archived tumor tissue specimens from the same patient cohort.
- Trial name
- NCT07587268
- Testing
- DNA Methylation Profiling, m6A Epitranscriptomic Profiling
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- City of Hope Medical Center
Cholangiocarcinoma, Biliary Stricture
DNA Methylation Biomarker for Diagnosis of Cholangiocarcinoma in Patients With Bile Duct Stricture
DNA methylation biomarker for diagnosis of cholangiocarcinoma in patients with bile duct stricture has high sensitivity and specificity compared with cytology from the brush specimens
- Conditions
- Cholangiocarcinoma, Biliary Stricture, DNA Methylation, Brush Cytology
- Trial name
- DNA (NCT04568512)
- Testing
- Control, Cholangiocarcinoma
- Where
- Thailand
- Volunteers
- 67 people
- Sponsor
- Mahidol University
Hematuria, Urothelial Carcinoma
Performance Evaluation of Urine DNA Methylation Testing for the Detection of Urothelial Carcinoma in Patients With Hematuria
Background Urothelial carcinoma (UC) is the most common malignancy of the urinary system. Hematuria is a significant clinical manifestation of UC, often diagnosed through invasive procedures.
- Conditions
- Hematuria, Urothelial Carcinoma, Bladder Cancer, Ureter Cancer
- Trial name
- NCT06469229
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- Changhai Hospital
Renal Cell Carcinoma, Benign Renal Mass
Plasma DNA Methylation for Preoperative Classification of Renal Masses
METH-RENAL is a prospective observational diagnostic development and threshold-setting study in adults with a renal mass scheduled for partial or radical nephrectomy.
- Trial name
- NCT07874542
- Where
- China
- Volunteers
- 240 people
- Sponsor
- RenJi Hospital
Prostate Cancer, Prostate Adenocarcinoma
Detection of Prostate Cancer With Non-invasive Method Based on DNA Methylation of Circulated Tumor DNA, PBMC
Prostate cancer is a leading cause of mortality and morbidity. The purpose of this study is to develop and test non-invasive biomarkers based on methylation changes in PBMC, T-cells and circulated tumor DNA in prostate cancer…
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Prostate Cancer Metastatic
- Trial name
- NCT03494803
- Where
- Kazakhstan
- Sponsor
- HKGepitherapeutics
Liver Fibrosis
Multiomics Study of Fibrosis Factors After Liver Transplantation and Exploration of Fibrosis Methylation Biomarkers
This is a retrospective observational study in liver transplantation recipients with or without allograft liver fibrosis. Based on the GM-seq and Tcr-Seq data, a novel diagnostic model including DNA-methylation and TCR-Seq…
- Trial name
- NCT05926778
- Testing
- Liver allograft fibrosis
- Where
- China
- Volunteers
- 60 people
- Sponsor
- RenJi Hospital
Colorectal Cancer, Polyps
Clinical Validation of Stool DNA-based SDC2 Methylation Test for Colorectal Cancer Detection
Pivotal trials of SDC2 methylation biomarker test in stool DNA to estimate clinical sensitivity and specificity in detection of colorectal cancer.
- Conditions
- Colorectal Cancer, Polyps, Other Cancers, Healthy
- Trial name
- NCT03146520
- Testing
- EarlyTect Colon Cancer
- Where
- South Korea
- Volunteers
- 634 people, healthy volunteers welcome
- Sponsor
- Genomictree, Inc.
Non Small Cell Lung Cancer
CTA Expression/Methylation and Response to Pembrolizumab of NSCLC Patients
Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
- Trial name
- NCT03571360
- Testing
- PD-L1 positive vs PD-L1 negative NSCLC patients
- Where
- Austria
- Volunteers
- 42 people
- Sponsor
- Medical University of Vienna
GVHD - Graft-Versus-Host Disease, Infections After HSCT
Cell Free DNA Profiling As a Tool to Monitor Clinically-Relevant Events in Allogeneic Hematopoietic Stem Cell Transplantation
Allogeneic hematopoietic stem cell transplantation (HSCT) is a life-saving treatment for people with severe blood-related diseases.
- Conditions
- GVHD - Graft-Versus-Host Disease, Infections After HSCT, Transplant Associated Microangiopathy TAM, Sinusoidal Obstruction Syndrome (SOS)
- Trial name
- NCT06715046
- Testing
- Sample collation for cfDNA methylation analysis, Sample collection for EV phenotype analysis
- Where
- 2 sites in Italy
- Volunteers
- 30 people
- Sponsor
- University of Turin, Italy